Has Rami Owera, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,621,169 in general payments to Rami Owera, MD across 999 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rami Owera, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rami Owera, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rami Owera, MD

Hematology & Oncology · Pensacola, FLNPI 1659399624

Payments from drug & device makers

$2,621,169in general payments, 2019–2025

Across 999 payments — averaging $2623.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$609K
Genentech, Inc.$571K
Mirati Therapeutics, Inc.$451K
Merck$216K
Amgen$147K
Takeda Pharmaceuticals U.S.A., Inc.$123K
plus $503K from 54 others

$11,600in research payments, 2019–2025

Across 20 payments — averaging $580.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Janssen Scientific Affairs, LLC$12K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	42	$609,490
Genentech, Inc.	74	$571,472
Mirati Therapeutics, Inc.	121	$450,954
Merck	56	$215,841
Amgen	14	$147,491
Takeda Pharmaceuticals U.S.A., Inc.	46	$122,515
AstraZeneca	35	$117,071
Janssen Research & Development, LLC	165	$70,300
G1 Therapeutics, Inc.	32	$41,021
Eli Lilly	9	$41,001
Gilead(2 entities)	28	$40,836
Beigene USA, Inc.	26	$34,787
Pfizer	26	$20,055
Beigene, Ltd.	8	$19,958
Veru Inc.	5	$17,289
Exelixis Inc.	27	$16,938
Johnson & Johnson(2 entities)	64	$12,614
EMD Serono, Inc.	8	$11,425
Viiv Healthcare Company	1	$9,500
Jazz Pharmaceuticals Inc.	3	$8,954
Seagen Inc.	3	$6,839
Pharmacyclics LLC, An Abbvie Company	6	$4,904
Ipsen Biopharmaceuticals, Inc	8	$4,707
GSK	8	$4,564
Beone Medicines USA, Inc.	5	$4,072
Bristol Myers Squibb	15	$3,656
Lilly USA, LLC	8	$2,678
Janssen Scientific Affairs, LLC	19	$2,121
Incyte Corporation	5	$1,623
Karyopharm Therapeutics Inc.	1	$1,550
Immunomedics, Inc.	1	$1,250
Adaptive Biotechnologies Corporation	6	$878
Novartis	36	$679
Astellas Pharma US Inc	15	$666
Eisai Inc.	12	$267
Sanofi	9	$169
Genentech USA, Inc.	8	$149
AbbVie	6	$144
Regeneron Healthcare Solutions, Inc.	6	$142
Daiichi Sankyo Inc.	3	$71
Stemline Therapeutics Inc.	3	$65
Boehringer Ingelheim	3	$57
Sumitomo Pharma America, Inc.	2	$43
AVEO Pharmaceuticals, Inc.	2	$42
Bayer	2	$38
Genmab U.S., Inc.	2	$35
CSL Behring	2	$26
Pharmacosmos Therapeutics Inc.	1	$24
Servier Pharmaceuticals LLC	1	$21
Tempus AI, Inc	1	$21
Blueprint Medicines Corporation	1	$20
Heron Therapeutics, Inc.	1	$19
Progenics Pharmaceuticals, Inc.	1	$19
Taiho Oncology, Inc.	1	$17
Myovant Sciences Inc.	1	$17
Novocure Inc.	1	$15
Springworks Therapeutics, Inc.	1	$13
Coherus Oncology, Inc.	1	$13
Teva Pharmaceuticals USA, Inc.	1	$12
Epizyme, Inc.	1	$12

How this compares

$2,621,169 in reported general payments places this provider in the 90th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$5,059,470

Medicare patients

1,164

Services billed

243,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Pensacola

Carl LandgrenMiami$47.8M
Julio ChavezTampa$16.4M
Steven AttiaJacksonville$13.9M
Santosh NairOrange City$13.5M
Frederick LockeTampa$12.8M
Tarek MekhailOrlando$11.2M
Carlos AlemanyOrlando$10.9M
Thomas GeorgeGainesville$10.3M
Sikander AilawadhiJacksonville$9.8M
Richard KimTampa$8.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →